Literature DB >> 2194459

Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanine6 angiotensin II.

R C Speth1, K H Kim.   

Abstract

Angiotensin II receptor binding sites in rat liver and PC12 cells differ in their affinities for a nonpeptidic antagonist, DuP 753, and p-aminophenylalanine6 angiotensin II. In liver, which primarily contains the sulfhydryl reducing agent-inhibited type of angiotensin II receptor, which we refer to as the AII alpha subtype, DuP 753 displays an IC50 of 55 nM, while p-aminophenylalanine6 angiotensin II displays an IC50 of 8-9 microM. In PC12 cells, which primarily contain the angiotensin II receptor type whose binding affinity is enhanced by sulfhydryl reducing agents (AII beta), DuP 753 displays an IC50 in excess of 100 microM, while p-aminophenylalanine6 angiotensin II displays an IC50 of 12 nM. p-Aminophenylalanine6 angiotensin II binding affinity in liver is decreased in the presence of guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) suggesting that this analogue is an agonist.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2194459     DOI: 10.1016/0006-291x(90)91993-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

1.  Pharmacological characterization of angiotensin II AT(2) receptor subtype heterogeneity in the rat adrenal cortex and medulla.

Authors:  X Lu; K L Grove; W Zhang; R C Speth
Journal:  Endocrine       Date:  1995-04       Impact factor: 3.633

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

3.  Bombesin, neuromedin B and neuromedin C interact with a common rat pancreatic phosphoinositide-coupled receptor, but are differentially regulated by guanine nucleotides.

Authors:  M C Sekar; N Uemura; D H Coy; B I Hirschowitz; K E Dickinson
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

4.  Saralasin and Sarile Are AT2 Receptor Agonists.

Authors:  Marie-Odile Guimond; Mathias Hallberg; Nicole Gallo-Payet; Charlotta Wallinder
Journal:  ACS Med Chem Lett       Date:  2014-08-18       Impact factor: 4.345

5.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

6.  Angiotensin II receptor subtypes are coupled with distinct signal-transduction mechanisms in neurons and astrocytes from rat brain.

Authors:  C Sumners; W Tang; B Zelezna; M K Raizada
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

7.  Expression of AT2 receptors in the developing rat fetus.

Authors:  E F Grady; L A Sechi; C A Griffin; M Schambelan; J E Kalinyak
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

8.  Renin-angiotensin system inhibitors protect against age-related changes in rat liver mitochondrial DNA content and gene expression.

Authors:  Elena M V de Cavanagh; Idhaliz Flores; Marcelo Ferder; Felipe Inserra; León Ferder
Journal:  Exp Gerontol       Date:  2008-08-15       Impact factor: 4.032

9.  Differential distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat brain during development.

Authors:  M A Millan; D M Jacobowitz; G Aguilera; K J Catt
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

10.  Potentiation of purinergic transmission by angiotensin in prostatic rat vas deferens.

Authors:  C S Sum; D C Wan; W T Cheung
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.